Clinical trials: Lymphoma, Lymphocytic, Small
Cancer
Voriconazole Compared With Itraconazole in Preventing Fungal Infections in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
RATIONALE: Antifungals, such as voriconazole and itraconazole, may be effective in preventing fungal infections in patients who are undergoing allogeneic stem cell transplantation.
- Trial name
- NCT00079222
- Testing
- itraconazole, voriconazole
- Where
- United States
- Sponsor
- Jonsson Comprehensive Cancer Center
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Pirtobrutinib for the Treatment of Elderly Patients With Chronic Lymphocytic Leukemia
This phase II trial studies how well pirtobrutinib works in treating elderly patients with chronic lymphocytic leukemia (CLL). Bruton tyrosine kinase (BTK) inhibitors such as ibrutinib, acalabrutinib, and zanubrutinib work by…
- Trial name
- NCT07685717
- Testing
- Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Jennifer Woyach
Lymphoma
Rituximab and Liposomal Doxorubicin in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Monoclonal antibodies, such as rituximab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread.
- Trial name
- NCT00244985
- Testing
- rituximab, pegylated liposomal doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 42 people
- Sponsor
- Roswell Park Cancer Institute
Follicular Lymphoma, Diffuse Large Cell Lymphoma
Phase II Safety and Efficacy Study of Single-agent AT-101 in Patients With Relapsed or Refractory B-cell Malignancies
This is an open-label, multicenter, phase II study to evaluate the safety and efficacy of single-agent AT-101 in patients with relapsed or refractory B-cell malignancies.
- Conditions
- Follicular Lymphoma, Diffuse Large Cell Lymphoma, Mantle Cell Lymphoma, Small Lymphocytic Lymphoma
- Trial name
- NCT00275431
- Testing
- AT-101
- Where
- 11 sites in United States
- Volunteers
- 50 people
- Sponsor
- Ascenta Therapeutics
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Mantle Cell Lymphoma
A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
This research study will be evaluating the safety and efficacy of a study drug called TGR-1202 in combination with a known drug ibrutinib, also known as Imbruvica, as a possible treatment for Chronic Lymphocytic Leukemia/Small…
- Trial name
- NCT02268851
- Testing
- TGR-1202, Ibrutinib
- Where
- 5 sites in United States
- Volunteers
- 45 people
- Sponsor
- Dana-Farber Cancer Institute
Lymphoma, Quality of Life
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
RATIONALE: Studying the long-term effects of cancer treatment in cancer survivors may help improve the ability to plan effective treatment and follow-up care.
- Trial name
- NCT00098566
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Fred Hutchinson Cancer Center
Chronic Myeloproliferative Disorders, Leukemia
Caregiver Support in the Quality of Life of Patients Who Are Undergoing Donor Bone Marrow Transplantation
RATIONALE: Questionnaires that measure quality-of-life may improve the health care team's ability to plan supportive care for patients undergoing donor bone marrow transplantation.
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm
- Trial name
- NCT00281801
- Testing
- psychosocial assessment and care, Quality of Life Assessments
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Case Comprehensive Cancer Center
Lymphoma
Etoposide in Treating Patients With Relapsed Non-Hodgkin's Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of etoposide in treating patients with relapsed…
- Trial name
- NCT00002880
- Testing
- Etoposide phosphate
- Where
- 4 sites in United States
- Volunteers
- 53 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Lymphocytic Leukemia
Everolimus and Alemtuzumab in Treating Patients With Recurrent Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Everolimus may stop the growth of cancer cells by blocking some of the signaling molecules needed for cell growth. Monoclonal antibodies, such as alemtuzumab, can bind to and kill malignant lymphocytes.
- Trial name
- NCT00935792
- Testing
- alemtuzumab, everolimus
- Where
- 2 sites in United States
- Volunteers
- 28 people
- Sponsor
- Mayo Clinic
Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma
Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma
This phase II clinical trial studies how well Akt inhibitor MK2206 works in treating patients with relapsed lymphoma. Akt inhibitor MK2206 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
- Conditions
- Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, B-cell Adult Acute Lymphoblastic Leukemia
- Trial name
- NCT01258998
- Testing
- Akt inhibitor MK2206, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 60 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Lymphocytic Leukemia, Small Lymphocytic Leukemia
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
This phase III trial compares the effect of adding sonrotoclax to zanubrutinib versus zanubrutinib alone for the treatment of patients with untreated chronic lymphoblastic leukemia (CLL)/small lymphocytic lymphoma (SLL).
- Trial name
- NCT07321652
- Testing
- Zanubrutinib, Sonrotoclax, Computed Tomography
- Where
- 224 sites in United States
- Volunteers
- 466 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11
Lenalidomide After Donor Bone Marrow Transplant in Treating Patients With High-Risk Hematologic Cancers
This phase I clinical trial is studying the side effects and the best dose of lenalidomide after donor bone marrow transplant in treating patients with high-risk hematologic cancer.
- Conditions
- Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21); (q22; q22.1); RUNX1-RUNX1T1
- Trial name
- NCT01254578
- Testing
- Laboratory Biomarker Analysis, Lenalidomide, Pharmacological Study
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Leukemia, Lymphoma
Pentostatin, Alemtuzumab, and Rituximab in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
RATIONALE: Drugs used in chemotherapy, such as pentostatin, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00669318
- Testing
- alemtuzumab, rituximab, pentostatin
- Where
- 3 sites in United States
- Volunteers
- 41 people
- Sponsor
- Mayo Clinic
Breast Cancer, Leukemia
Phase I/II Study of Escalating-Dose Melphalan w/Autologous SCS & Amifostine Cytoprotect
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Conditions
- Breast Cancer, Leukemia, Lymphoma, Neuroblastoma
- Trial name
- NCT00003425
- Testing
- filgrastim, amifostine trihydrate, cyclophosphamide
- Where
- 4 sites in United States
- Volunteers
- 25 people
- Sponsor
- University of Kentucky
Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma
Immune Responses to COVID-19 Vaccination in Lymphoma Patients
This prospective observational study aims to evaluate the robustness and persistence of immune responses to vaccination, define factors associated with impaired immune responses and assess the incidence of COVID-19 infections in…
- Conditions
- Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Primary Mediastinal B Cell Lymphoma, High-grade B-cell Lymphoma
- Trial name
- PROSECO (NCT04858568)
- Where
- 9 sites in United Kingdom
- Volunteers
- 592 people
- Sponsor
- University Hospital Southampton NHS Foundation Trust
Leukemia, Lymphoma
Combination Chemotherapy and Rituximab in Treating Patients With Chronic Lymphocytic Leukemia or Lymphocytic Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Monoclonal antibodies can locate cancer cells and either kill them or deliver cancer-killing substances to…
- Trial name
- NCT00049413
- Testing
- rituximab, cyclophosphamide, pentostatin
- Where
- United States
- Sponsor
- Hoag Memorial Hospital Presbyterian
B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia
Fludarabine Phosphate and Total-Body Irradiation Before Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
This clinical trial studies how well giving fludarabine phosphate together with total-body irradiation (TBI) before donor peripheral blood stem cell transplant works in treating patients with chronic lymphocytic leukemia or small…
- Conditions
- B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
- Trial name
- NCT00060424
- Testing
- Cyclosporine, Fludarabine Phosphate, Hematopoietic Cell Transplantation
- Where
- 3 sites in United States, Italy
- Volunteers
- 21 people
- Sponsor
- Fred Hutchinson Cancer Center
Lymphoma
Melphalan, Yttrium Y 90 Ibritumomab Tiuxetan, and Rituximab Followed by Autologous Stem Cell Transplant in Treating Older Patients With Non-Hodgkin's Lymphoma That Has Relapsed or Not Responded to Previous Treatment
RATIONALE: Giving chemotherapy drugs, such as melphalan, before an autologous stem cell transplant helps stop the growth of cancer cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00392691
- Testing
- ibritumomab tiuxetan, rituximab, melphalan
- Where
- 10 sites in Switzerland
- Volunteers
- 20 people
- Sponsor
- Swiss Cancer Institute
Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma
Phase II MOR00208 in Combination With Lenalidomide for Patients With Relapsed or Refractory CLL, SLL or PLL or Older Patients With Untreated CLL, SLL or PLL
This phase II trial studies how well anti-cluster of differentiation (CD)19 monoclonal antibody MOR00208 and lenalidomide work in treating patients with relapsed, refractory, or previously untreated chronic lymphocytic leukemia…
- Conditions
- Contiguous Stage II Small Lymphocytic Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma
- Trial name
- NCT02005289
- Testing
- MOR00208, lenalidomide, Correlative Studies
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Lymphoma
Bone Marrow Transplantation in Treating Patients With Lymphoma
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage cancer cells, and may be an effective treatment for…
- Trial name
- NCT00002829
- Testing
- Recombinant Interferon Alfa, Cyclophosphamide, Etoposide
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center